Literature DB >> 15723037

Modulation of human nuclear receptor LRH-1 activity by phospholipids and SHP.

Eric A Ortlund1, Yoonkwang Lee, Isaac H Solomon, Janet M Hager, Rachid Safi, Yunhee Choi, Ziqiang Guan, Ashutosh Tripathy, Christian R H Raetz, Donald P McDonnell, David D Moore, Matthew R Redinbo.   

Abstract

The human nuclear receptor liver receptor homolog 1 (hLRH-1) plays an important role in the development of breast carcinomas. This orphan receptor is efficiently downregulated by the unusual co-repressor SHP and has been thought to be ligand-independent. We present the crystal structure at a resolution of 1.9 A of the ligand-binding domain of hLRH-1 in complex with the NR box 1 motif of human SHP, which we find contacts the AF-2 region of hLRH-1 using selective structural motifs. Electron density indicates phospholipid bound within the ligand-binding pocket, which we confirm using mass spectrometry of solvent-extracted samples. We further show that pocket mutations reduce phospholipid binding and receptor activity in vivo. Our results indicate that hLRH-1's control of gene expression is mediated by phospholipid binding, and establish hLRH-1 as a novel target for compounds designed to slow breast cancer development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15723037     DOI: 10.1038/nsmb910

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  79 in total

Review 1.  Targeting orphan nuclear receptors for treatment of metabolic diseases and autoimmunity.

Authors:  Thomas P Burris; Scott A Busby; Patrick R Griffin
Journal:  Chem Biol       Date:  2012-01-27

2.  Antidiabetic phospholipid-nuclear receptor complex reveals the mechanism for phospholipid-driven gene regulation.

Authors:  Paul M Musille; Manish Pathak; Janelle L Lauer; William H Hudson; Patrick R Griffin; Eric A Ortlund
Journal:  Nat Struct Mol Biol       Date:  2012-04-15       Impact factor: 15.369

Review 3.  Orphan nuclear receptors as targets for drug development.

Authors:  Subhajit Mukherjee; Sridhar Mani
Journal:  Pharm Res       Date:  2010-04-06       Impact factor: 4.200

Review 4.  Emerging actions of the nuclear receptor LRH-1 in the gut.

Authors:  Pablo J Fernandez-Marcos; Johan Auwerx; Kristina Schoonjans
Journal:  Biochim Biophys Acta       Date:  2010-12-29

Review 5.  Endogenous ligands for nuclear receptors: digging deeper.

Authors:  Michael Schupp; Mitchell A Lazar
Journal:  J Biol Chem       Date:  2010-10-18       Impact factor: 5.157

6.  Liver receptor homolog 1 is a negative regulator of the hepatic acute-phase response.

Authors:  Nicolas Venteclef; Jason C Smith; Bryan Goodwin; Philippe Delerive
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

7.  LRH-1-mediated glucocorticoid synthesis in enterocytes protects against inflammatory bowel disease.

Authors:  Agnes Coste; Laurent Dubuquoy; Romain Barnouin; Jean-Sebastien Annicotte; Benjamin Magnier; Mario Notti; Nadia Corazza; Maria Cristina Antal; Daniel Metzger; Pierre Desreumaux; Thomas Brunner; Johan Auwerx; Kristina Schoonjans
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

8.  Crystal Structures of the Nuclear Receptor, Liver Receptor Homolog 1, Bound to Synthetic Agonists.

Authors:  Suzanne G Mays; C Denise Okafor; Richard J Whitby; Devrishi Goswami; Józef Stec; Autumn R Flynn; Michael C Dugan; Nathan T Jui; Patrick R Griffin; Eric A Ortlund
Journal:  J Biol Chem       Date:  2016-09-30       Impact factor: 5.157

9.  Solution Nuclear Magnetic Resonance Studies of the Ligand-Binding Domain of an Orphan Nuclear Receptor Reveal a Dynamic Helix in the Ligand-Binding Pocket.

Authors:  Nicolas Daffern; Zhonglei Chen; Yongbo Zhang; Leslie Pick; Ishwar Radhakrishnan
Journal:  Biochemistry       Date:  2018-03-22       Impact factor: 3.162

10.  Nutrient-dependent phosphorylation channels lipid synthesis to regulate PPARα.

Authors:  Anne P L Jensen-Urstad; Haowei Song; Irfan J Lodhi; Katsuhiko Funai; Li Yin; Trey Coleman; Clay F Semenkovich
Journal:  J Lipid Res       Date:  2013-04-13       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.